 |
MR Vol.12 No.3 indexに戻る
 |
MODERN RHEUMATOLOGY
Vol.12 No.3 |
 |
|
|
 |
|
|
Activated peripheral blood mononuclear cells
detected in lupus patients using cDNA coding for proliferating cell
nuclear antigen |
|
|
| Y. Takasaki A1, S. Ando A1, K. Matsumoto A1,
H. Yamada A1, K. Ikeda A1, M. Nawata A1, M. Matsushita A1, R. Matsudaira
A1, K. Kaneda A1, K. Takeuchi A1, Y. Tokano A1, H. Hashimoto A1 |
| A1 Department of Internal Medicine and Rheumatology,
Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo
113-8421, Japan Tel. +81-3-3813-3111 (ext. 3314); Fax +81-3-5800-4893
e-mail: tyoshi@med.juntendo.ac.jp |
| |
| Abstract |
| Abstract The expression of proliferating cell
nuclear antigen (PCNA) mRNA in peripheral blood mononuclear cells
(PBMCs) from patients with systemic lupus erythematosus (SLE) was
measured by dot blot hybridization using a PCNA cDNA, and correlated
with the percentage of PCNA-positive cells detected immunohistochemically
using a monoclonal anti-PCNA antibody. PCNA-positive PBMCs were detected
in 72.2% of SLE patients (n = 36), which is significantly more than
among healthy controls. In addition, among those in whom PCNA expression
was detected, the percentage of PBMCs expressing PCNA was significantly
higher in SLE patients (mean 2.5% vs. 0.15%). The level of PCNA mRNA
was increased in PBMCs from 83.3% of SLE patients, and was significantly
correlated with the percentage of PCNA-positive cells (r = 0.54,
P < 0.01) and with the disease activity score (r = 0.56, P < 0.01).
A longitudinal study of two SLE patients confirmed that PCNA mRNA
expression and the percentages of PCNA-positive cells varied in parallel
with disease activity. Thus, an analysis of activated PBMCs from
SLE patients using PCNA cDNA may be a useful method by which to estimate
SLE disease activity. |
| |
| Key words |
| Key words Anti-PCNA monoclonal antibodies
・ Disease activity ・ PCNA cDNA・ Proliferating cell nuclear antigen
(PCNA) ・ Systemic
lupus erythematosus (SLE) |
|
|
 |
|
|
